Island Pharmaceuticals Ltd has released a press release.
$1.95million Fully Underwritten Rights Issue
Filed with ASX ·
6ix hasn’t read this filing yet.
Island Pharmaceuticals Ltd on 6ix
Earlier from Island Pharmaceuticals
- Island investor presentation
- Dosing complete in ISLA-101 SAD study
- Quarterly Activity Report and Appendix 4C
- Third cohort dosed in ISLA-101 Single Ascending Dose study
- Approval to commence dosing 3rd cohort of ISLA-101 SAD study
Later from Island Pharmaceuticals
- Prospectus
- Island Pharmaceuticals to raise $1.95 million for ISLA-101 development
- Security Class Suspension from Quotation ILAO
- Security Class Reinstatement to Quotation ILAO
- Positive data from ISLA-101 Single Ascending Dose study
Follow Island Pharmaceuticals into a list and get an email when it puts out news.
Follow Island Pharmaceuticals